FDA and CDC announce a pause in administering the Johnson & Johnson coronavirus vaccine
During a media call with members of the Food and Drug Administration and the Centers for Disease Control and Prevention, acting FDA Commissioner Janet Woodcock said that the agencies were recommending a pause in the administration of the Johnson & Johnson vaccine for COVID-19 because of reports of blood clots.
Video Transcript
JANET WOODCOCK: This morning, the FDA and CDC announced, that out of an abundance of caution, we're recommending a pause in the use of the Johnson & Johnson COVID-19 vaccine due to reports of six cases of a rare and severe type of blood clot following vaccine administration.
We're recommending this pause while we work together to fully understand these events, and also so we can get information out to health care providers and vaccine recipients.
Right now, I'd like to stress, these events appear to be extremely rare. However, COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of adverse events following vaccination very seriously.
